Trial record 2 of 40 for:    "Sleep Disorders, Circadian Rhythm"

Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT00593736
First received: January 2, 2008
Last updated: February 27, 2012
Last verified: February 2012
  Purpose

The purpose of this study is to evaluate the ability of ramelteon, once daily (QD), to advance the timing of sleep in individuals with delayed sleep phase syndrome.


Condition Intervention Phase
Sleep Disorders, Circadian Rhythm
Drug: Ramelteon
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel, Proof of Concept Study to Evaluate the Effectiveness of Ramelteon to Advance the Timing of Sleep in Individuals With Delayed Sleep Phase Syndrome (DSPS)

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    The elapsed time from the beginning of the polysomnography recording to the onset of the first 10 minutes of continuous sleep (ie, total number of epochs before the first 20 consecutive non-wake epochs divided by 2).


Secondary Outcome Measures:
  • Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    The elapsed time from the beginning of the polysomnography recording to the onset of the first 10 minutes of continuous sleep (ie, total number of epochs before the first 20 consecutive non-wake epochs divided by 2).

  • Total Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    The sum of all of the minutes of Stages 1, 2, 3, 4, and rapid eye movement (REM) sleep.

  • Total Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    The sum of all of the minutes of Stages 1, 2, 3, 4, and REM sleep.

  • Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-3 Hours) (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    The total sleep time divided by time-in-bed, multiplied by 100.

  • Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-3 Hours) (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    The total sleep time divided by time-in-bed, multiplied by 100.

  • Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-8 Hours) (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    The total sleep time divided by time-in-bed, multiplied by 100.

  • Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-8 Hours) (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    The total sleep time divided by time-in-bed, multiplied by 100.

  • Wake Time After Sleep Onset Over a 2-night Average Measured by Polysomnography (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    The number of wake minutes after the onset of persistent sleep prior to the end of recording.

  • Wake Time After Sleep Onset Over a 2-night Average Measured by Polysomnography (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    The number of wake minutes after the onset of persistent sleep prior to the end of recording.

  • Number of Awakenings Over a 2-night Average Measured by Polysomnography (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    The number of times after onset of persistent sleep that there is a wake entry of at least 2 epochs in duration. Each entry must be separated by stage 2, stage 3/4 non-REM (NREM) sleep, or REM sleep to be counted.

  • Number of Awakenings Over a 2-night Average Measured by Polysomnography (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    The number of times after onset of persistent sleep that there is a wake entry of at least 2 epochs in duration. Each entry must be separated by stage 2, stage 3/4 non-REM (NREM) sleep, or REM sleep to be counted.

  • Total Wake Time Over a 2-night Average Measured by Polysomnography (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    The sum of all the minutes of Stage Wake from the beginning of the recording to the end of recording.

  • Total Wake Time Over a 2-night Average Measured by Polysomnography (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    The sum of all the minutes of Stage Wake from the beginning of the recording to the end of recording.

  • Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Sleep time was measured as the clock time the subject went to sleep. Units are hours and minutes on a 24-hour clock, expressed in decimal time.

  • Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Sleep time was measured as the clock time the subject went to sleep. Units are hours and minutes on a 24-hour clock, expressed in decimal time.

  • Wake Time Over a 2-night Average Measured by Polysomnography (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Wake Time was measured as the clock time that the subject got up in the morning. Units are hours and minutes on a 24-hour clock, expressed in decimal time.

  • Wake Time Over a 2-night Average Measured by Polysomnography (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Wake Time was measured as the clock time that the subject got up in the morning. Units are hours and minutes on a 24-hour clock, expressed in decimal time.

  • Total Sleep Time Measured by Actigraphy (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Total sleep time calculated using the total number of epochs (number of movements recorded by actigraphy watch worn by subject) that are less than or equal to 40, measured between the start time and end time during the nocturnal sleep interval, scored as SLEEP by the actigraphy software.

  • Total Sleep Time Measured by Actigraphy (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Total sleep time pertains to the total number of epochs (number of movements recorded by actigraphy watch worn by subject) that are less than or equal to 40, measured between the start time and end time during the nocturnal sleep interval, scored as SLEEP by the actigraphy software.

  • Sleep Efficiency Measured by Actigraphy (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Sleep efficiency pertains to the scored total sleep time (recorded by actigraphy watch worn by subject) of the sleep interval divided by total time in bed minus total invalid time (Sleep/Wake), multiplied by 100.

  • Sleep Efficiency Measured by Actigraphy (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Sleep efficiency pertains to the scored total sleep time (recorded by actigraphy watch worn by subject) of the sleep interval divided by total time in bed minus total invalid time (Sleep/Wake), multiplied by 100.

  • Wake Time During Sleep Interval Measured by Actigraphy (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Wake time during sleep is the total number of epochs (number of movements recorded by actigraphy watch worn by subject) between the start time and the end time of the given sleep interval, scored as WAKE by the software (or manually set as WAKE by the practitioner using the software), multiplied by the Epoch length in minutes.

  • Wake Time During Sleep Interval Measured by Actigraphy (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Wake time during sleep is the total number of epochs (number of movements recorded by actigraphy watch worn by subject) between the start time and the end time of the given sleep interval, scored as WAKE by the software (or manually set as WAKE by the practitioner using the software), multiplied by the Epoch length in minutes.

  • Wake Bouts Measured by Actigraphy (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    The number of wake bouts pertains to the total number of continuous blocks (recorded by actigraphy watch worn by subject), with one or more epochs in duration, and with each epoch of each clock scored as WAKE between the start time and the end time of the given interval.

  • Wake Bouts Measured by Actigraphy (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    The number of wake bouts pertains to the total number of continuous blocks (recorded by actigraphy watch worn by subject), with one or more epochs in duration, and with each epoch of each clock scored as WAKE between the start time and the end time of the given interval.

  • Sleep Latency Measured by Actigraphy (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    The elapsed time from the beginning of the recording to the onset of the first 10 minutes of continuous sleep (recorded by actigraphy watch worn by subject).

  • Sleep Latency Measured by Actigraphy (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    The elapsed time from the beginning of the recording to the onset of the first 10 minutes of continuous sleep (recorded by actigraphy watch worn by subject).

  • Sleep Time Measured by Actigraphy (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Clock time subject goes to sleep (recorded by actigraphy watch worn by subject). Units are hours and minutes on a 24-hour clock, expressed in decimal time.

  • Sleep Time Measured by Actigraphy (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Clock time subject goes to sleep (recorded by actigraphy watch worn by subject). Units are hours and minutes on a 24-hour clock, expressed in decimal time.

  • Wake Time Measured by Actigraphy (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Clock time subject wakes up (recorded by actigraphy watch worn by subject). Units are hours and minutes on a 24-hour clock, expressed in decimal time.

  • Wake Time Measured by Actigraphy (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Clock time subject wakes up (recorded by actigraphy watch worn by subject). Units are hours and minutes on a 24-hour clock, expressed in decimal time.

  • Subjective Sleep Latency Measured by a Post-sleep Questionnaire (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Subjective sleep latency was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How long do you think it took you to fall asleep last night?"

  • Subjective Sleep Latency Measured by a Post-sleep Questionnaire (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Subjective sleep latency was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How long do you think it took you to fall asleep last night?"

  • Subjective Total Sleep Time Measured by a Post-sleep Questionnaire (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Subjective total sleep time was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How long (total hours and minutes) do you think you slept last night?"

  • Subjective Total Sleep Time Measured by a Post-sleep Questionnaire (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Subjective total sleep time was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How long (total hours and minutes) do you think you slept last night?"

  • Subjective Wake Time After Sleep Onset Measured by a Post-sleep Questionnaire (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Subjective wake time after sleep onset was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "Did you wake up during the night? If "yes", what is the total time you think you were awake?"

  • Subjective Wake Time After Sleep Onset Measured by a Post-sleep Questionnaire (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Subjective wake time after sleep onset was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "Did you wake up during the night? If "yes", what is the total time you think you were awake?"

  • Subjective Number of Awakenings Measured by a Post-sleep Questionnaire (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Subjective number of awakenings was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "Did you wake up during the night? If "yes", how many times do you think you woke up?"

  • Subjective Number of Awakenings Measured by a Post-sleep Questionnaire (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Subjective number of awakenings was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "Did you wake up during the night? If "yes", how many times do you think you woke up?"

  • Subjective Sleep Quality Measured by a Post-sleep Questionnaire (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Subjective sleep quality was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How would you describe the quality of your sleep last night?" Scores were based on the following scale: Extremely Poor=7; Very Poor=6; Poor=5; Fair=4; Good=3; Very Good=2; Excellent=1.

  • Subjective Sleep Quality Measured by a Post-sleep Questionnaire (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Subjective sleep quality was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How would you describe the quality of your sleep last night?" Scores were based on the following scale: Extremely Poor=7; Very Poor=6; Poor=5; Fair=4; Good=3; Very Good=2; Excellent=1.

  • Subjective Sleep Time Measured by a Post-sleep Questionnaire (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Subjective sleep time was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "What time did you try to go to sleep last night?" Units are hours and minutes on a 24-hour clock, expressed in decimal time.

  • Subjective Sleep Time Measured by a Post-sleep Questionnaire (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Subjective sleep time was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "What time did you try to go to sleep last night?" Units are hours and minutes on a 24-hour clock, expressed in decimal time.

  • Subjective Getting up in the Morning Measured by a Post-sleep Questionnaire (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    The score was an average of 2 nights responses. If subjects had a work or school day, the answer to, "How easy was it for you to wake or get up in the morning when on a school or working night?" was based on the following scale: Extremely Difficult =7; Very Difficult =6; Difficult =5; Neither =4; Easy =3; Very Easy =2; Extremely Easy =1.

  • Subjective Getting up in the Morning Measured by a Post-sleep Questionnaire (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    The score was an average of 2 nights responses. If subjects had a work or school day, the answer to, "How easy was it for you to wake or get up in the morning when on a school or working night?" was based on the following scale: Extremely Difficult =7; Very Difficult =6; Difficult =5; Neither =4; Easy =3; Very Easy =2; Extremely Easy =1.

  • Subjective Ability to Concentrate in the Morning Measured by a Post-sleep Questionnaire (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Subjective ability to concentrate was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How would you describe your ability to concentrate this morning?" Scores were based on the following scale: Extremely Poor=7; Very Poor=6; Poor=5; Fair=4; Good=3; Very Good=2; Excellent=1.

  • Subjective Ability to Concentrate in the Morning Measured by a Post-sleep Questionnaire (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Subjective ability to concentrate was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How would you describe your ability to concentrate this morning?" Scores were based on the following scale: Extremely Poor=7; Very Poor=6; Poor=5; Fair=4; Good=3; Very Good=2; Excellent=1.

  • Subjective Level of Alertness Measured by a Post-sleep Questionnaire (Nights 6-7) [ Time Frame: Nights 6-7 ] [ Designated as safety issue: No ]
    Subjective level of alertness was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How would you describe your level of alertness this morning?" Scores were based on the following scale: Extremely Poor=7; Very Poor=6; Poor=5; Fair=4; Good=3; Very Good=2; Excellent=1.

  • Subjective Level of Alertness Measured by a Post-sleep Questionnaire (Nights 13-14) [ Time Frame: Nights 13-14 ] [ Designated as safety issue: No ]
    Subjective level of alertness was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How would you describe your level of alertness this morning?" Scores were based on the following scale: Extremely Poor=7; Very Poor=6; Poor=5; Fair=4; Good=3; Very Good=2; Excellent=1.

  • Next Morning Residual Effects Assessments of Psychomotor and Cognitive Function Via Digit Symbol Substitution Test [ Time Frame: Day 15 ] [ Designated as safety issue: No ]
    The number of correct digit-for-number substitutions on a Digit Symbol Substitution Test in the 90-second period was recorded to assess psychomotor and cognitive function. The score was the average of 2 mornings' tests. Worst Value: 0. Best Value: No Limit.

  • Next Morning Residual Effects Assessments of Psychomotor and Cognitive Function Via Memory Recall Test--Immediate [ Time Frame: Day 15 ] [ Designated as safety issue: No ]
    After 16 words were read to a subject, a subject was given 2 minutes to write down as many words as he/she remembered. The correct number of words written was scored, and the average of 2 mornings' tests was calculated.

  • Next Morning Residual Effects Assessments of Psychomotor and Cognitive Function Via Memory Recall Test--Delayed [ Time Frame: Day 15 ] [ Designated as safety issue: No ]
    After 16 words were read to a subject, a subject waited 1 minute and then was given 2 minutes to write down as many words as he/she remembered. The correct number of words written was scored, and the average of 2 mornings' tests was calculated.

  • Visual Analogue Scale for Mood [ Time Frame: Day 15 ] [ Designated as safety issue: No ]
    Subjects marked visual scales (in millimeters) that represented ranges of emotions (eg, calm to anxious; normal to bloated; energetic to fatigued). Individual subject composite scores were calculated, and the average of 2 tests were analyzed. Worst Value: 0 mm. Best Value: 100 mm. The farther to the left a subject marks, the better their mood; farther to the right, the more distressed the mood. Higher numbers indicate a more distressed mood.

  • Visual Analogue Scale for Feelings [ Time Frame: Day 15 ] [ Designated as safety issue: No ]
    Subjects marked visual scales (in millimeters) that represented ranges of emotions (eg, calm to anxious; normal to bloated; energetic to fatigued). Individual subject composite scores were calculated, and the average of 2 tests were analyzed. Worst Value:0 mm.. Best Value:100 mm.. The farther to the left a subject marks, the better their mood; farther to the right, the more distressed the mood. Higher numbers indicate a more distressed mood.

  • The Time of Dim Light Melatonin Secretion Onset [ Time Frame: Day 15 ] [ Designated as safety issue: No ]
    Linear Dim Light Melatonin Secretion Onset is defined as the first time of the evening (on a 24-hour clock) when the melatonin level rises above 3.0 pg/ml with a positive slope. Units are hours and minutes on a 24-hour clock, expressed in decimal time.

  • The Time of Dim Light Melatonin Secretion Offset [ Time Frame: Day 15 ] [ Designated as safety issue: No ]
    Dim Light Melatonin Secretion Offset is defined as the first time of the morning (on a 24-hour clock) when the melatonin drops to below 3 pg/mL with a negative slope. Units are hours and minutes on a 24-hour clock, expressed in decimal time.

  • The Total Duration of Secretion of Melatonin [ Time Frame: Day 15 ] [ Designated as safety issue: No ]
    The total duration of time from Dim Light Melatonin Secretion Onset to Dim Light Melatonin Secretion Offset.

  • The Area Under the Concentration-time Curve of Melatonin From 0 to 24 Hours [ Time Frame: Day 15 ] [ Designated as safety issue: No ]
    Area under the concentration-time curve is a measure of total drug exposure.

  • Average Cmax (Maximum Observed Plasma Concentration) Calculated as the Average of Three Highest Cmax Observations Within the Sampling Period. [ Time Frame: Day 15 ] [ Designated as safety issue: No ]
    Average Cmax calculated as the average of three highest Cmax observations within the sampling period.


Enrollment: 132
Study Start Date: October 2007
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ramelteon 1 mg QD Drug: Ramelteon
Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
Other Names:
  • Ramelteon
  • Rozerem™
  • TAK-375
Experimental: Ramelteon 4 mg QD Drug: Ramelteon
Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
Other Names:
  • Ramelteon
  • Rozerem™
  • TAK-375
Experimental: Ramelteon 8 mg QD Drug: Ramelteon
Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
Other Names:
  • Ramelteon
  • Rozerem™
  • TAK-375
Placebo Comparator: Placebo QD Drug: Placebo
Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.

Detailed Description:

Delayed sleep phase syndrome is the most common circadian disorder in adolescents and most adults with the condition report onset of symptoms during childhood or adolescence. Delayed Sleep Phase Syndrome involves a chronic mismatch between the usual daily schedule required by the individual's environment and his or her circadian sleep wake pattern. Individuals suffering from delayed Sleep Phase Syndrome experience great difficulty when attempting to fall asleep before 1-2 am, if not later, as well as rising at acceptable hours of the morning despite having completely normal sleep architecture and sleep duration. Delayed Sleep Phase Syndrome is a sleep disorder that results from a dysregulation of the circadian sleep-wake rhythm. Delayed Sleep Phase Syndrome is often the cause of severe insomnia and is associated with excessive daytime sleepiness, major depressive disorder and severe disruption of education, work and social functioning. Its major symptom is extreme difficulty initiating sleep at a conventional hour and waking on time in the morning for school or work.

Ramelteon is a selective melatonin type 1 (MT1) and type 2 (MT2) receptor agonist. The purpose of this study is to evaluate the ability of ramelteon to advance the timing of sleep in individuals with delayed sleep phase syndrome. The effect of ramelteon will be analyzed based on collection of information from a post-sleep questionnaire completed by participants, and data collected by polysomnography in a sleep clinic setting. Total participation time involved in this study will be approximately 7 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Females of childbearing potential who is sexually active must agree to use adequate contraception from screening throughout the duration of the study.
  • Must have a diagnosis of Delayed Sleep Phase Syndrome according to International Classification of Sleep Disorders criteria for at least 3 months.
  • Based on sleep history, subject's habitual sleep time is more than 3 hours later than the desired sleep time.
  • Must have had self reported insomnia which is defined per the sleep history as his or her sleep latency of at least 45 minutes when attempting to sleep at desired sleep time required by his or her work or school schedule.
  • The subjective sleep latency via Post sleep questionnaire during outpatient screening period must be greater than or equal to 45 minutes during every working night or school night provided the subject went to bed at their desired sleep time.
  • During single blind placebo run-in Polysomnography screening nights, subject is instructed to go to bed at their desired bed time and must demonstrate difficulty in falling asleep based on the following criteria:

    • During Polysomnography screening nights when the subject goes to bed at their desired sleep time or
    • The average of total wake time
  • Is in good health as determined by a medical and psychiatric history, physical examination, Electrocardiogram, and serum chemistry and hematology.
  • Is able to complete self-rating scales via interactive voice response system, and has a touch tone phone.
  • Is willing to comply with study procedures and restrictions with fixed sleep time and wake time during the study and to attend regularly scheduled clinic visits as specified in this protocol.
  • Has a body mass index is between 18 and 34 kg/m2, inclusive.
  • Has a negative urine test result for selected substances of abuse (including alcohol).
  • Has a negative test result for hepatitis B surface antigen and hepatitis C virus antibody or history of human immunodeficiency virus.
  • Has not used pharmacological sleep assistance for more than 4 times/week during the 3 months prior to Initial Screening.
  • Must have discontinued use of all pharmacological sleep aids beginning 1 week prior to Visit 2 and for the duration of the trial.

Exclusion Criteria:

  • Has a known hypersensitivity to ramelteon or related compounds, including melatonin and melatonin-related compounds or 5-hydroxytryptophan.
  • Has participated in any other investigational study and/or taken any investigational drug within 30 days or 5 half-lives prior to the first dose of study medication, whichever is longer.
  • Has flown across greater than 3 time zones within the past 3 months prior to administration of study medication.
  • Has sleep schedule changes required by employment (eg, shift worker) within 3 months prior to the administration of study medication.
  • Has participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to the administration of study medication.
  • Has a history of alcohol abuse within the past 12 months, as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, or regularly consumes more than 14 alcoholic drinks per week or consumes any alcoholic drinks within 24 hours of Screening Visit.
  • Has a history of drug abuse within the past 12 months.
  • Has a current, clinically significant neurological (including cognitive), hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic disease, as determined by the investigator.
  • Has a probable current diagnosis of another circadian rhythm disorder or a sleep disorder other than Delayed Sleep Phase Syndrome that is the primary cause of insomnia.
  • Had an apnea hypopnea index greater than 10 on the first night of Polysomnography Screening.
  • Has periodic limb movements during sleep with arousal index greater than 10 as seen on the first night of Polysomnography screening only.
  • Has a positive urine drug screen or breathalyzer test.
  • Has ever had a history of seizures; sleep apnea, restless leg syndrome, chronic obstructive pulmonary disease, fibromyalgia, or a positive test result for the aforementioned ailments on the screening Polysomnography, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.
  • Has a history of psychiatric disorder (including anxiety or depression) within the past 12 months.
  • Smokes more than 3 cigarettes per day or uses tobacco products during nightly awakenings.
  • Routinely consumes caffeine including coffee, tea and/or other caffeine-containing beverages or food averaging more than 600 mg of caffeine per day.
  • Has used any central nervous system drug or other medications, including those used to treat psychiatric disorders, known to affect sleep/wake function within 1 week whichever is longer prior to the administration of single blind study drug.
  • Used melatonin, or other drugs/supplements known to affect sleep/wake function within 1 week (or 5 half lives of the drug) whichever is longer prior to the first dose of single blind medication.
  • Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • Anxiolytics
    • Hypnotics
    • Antidepressants
    • Anticonvulsants
    • Sedating H1 antihistamines
    • Systemic steroids
    • Respiratory stimulants
    • Decongestants
    • Antipsychotics
    • Muscle relaxants
    • Over-the-counter and prescription diet aids
    • Narcotic analgesics
    • Beta Blockers
    • St. John's wort
    • Kava kava
    • Ginkgo biloba
    • Modafinil
    • Coumadin
    • Heparin
    • Melatonin and all other drugs or supplements known to affect sleep/wake function will be prohibited within 1 week of the first dose of study medication and during the entire study.
  • Has any clinically important abnormal finding as determined by a medical history, physical examination, Electrocardiogram, or clinical laboratory tests as determined by the investigator.
  • Has a positive hepatitis panel including anti- Hepatitis A Virus, hepatitis B surface antigen or anti- hepatitis C virus.
  • Has any additional condition(s) that in the investigator's opinion would:

    • Affect sleep/wake function
    • Prohibit the subject from completing the study, or
    • Not be in the best interest of the subject.
  • Exhibits a placebo response during single-blinded placebo run in period.
  • Individuals with a habitual sleep time later than 4:00 am should not be included in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00593736

  Show 42 Study Locations
Sponsors and Collaborators
Takeda
Investigators
Study Director: Medical Director Clinical Science Takeda
  More Information

Additional Information:
No publications provided

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT00593736     History of Changes
Other Study ID Numbers: 01-04-TL-375-044
Study First Received: January 2, 2008
Results First Received: July 31, 2009
Last Updated: February 27, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Delayed sleep phase syndrome; drug therapy

Additional relevant MeSH terms:
Sleep Disorders, Circadian Rhythm
Sleep Disorders
Parasomnias
Syndrome
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Mental Disorders
Disease
Pathologic Processes
Chronobiology Disorders
Dyssomnias
Occupational Diseases

ClinicalTrials.gov processed this record on October 19, 2014